Zydus Therapeutics Inc.
- Address
- 73c Route 31 North
Sponsor Overview
Specializations
Primary Biliary Cholangitis
Zydus Therapeutics Inc. is active in hepatology through clinical research focused on Primary Biliary Cholangitis, a chronic autoimmune liver disease affecting bile duct function and liver biochemistry.
- Cholestatic liver disease
- Bile duct inflammation
- Alkaline phosphatase
- Total bilirubin
The sponsor’s work in this area centers on biochemical response and liver-related disease control within autoimmune liver disorders.
Amyotrophic Lateral Sclerosis
The company also supports research in neurology, with a therapeutic focus on Amyotrophic Lateral Sclerosis, a progressive motor neuron disease associated with loss of muscle function and declining mobility.
- Neuromuscular function
- Functional decline
- Survival outcomes
- ALSFRS-R
Its clinical activity reflects interest in disease progression, functional assessment, and outcomes relevant to neurodegenerative disorders.
Inflammatory and Metabolic Pathways
Zydus Therapeutics Inc. is engaged in therapeutic areas connected to inflammation, metabolic regulation, and lipid-related biology, as reflected in its studies across liver and neuromuscular disease settings.
- Inflammatory signaling
- Metabolic modulation
- Liver biochemistry
- Systemic disease mechanisms
These areas indicate a research emphasis on conditions where immune, metabolic, and tissue-specific pathways contribute to clinical burden.
Multinational Clinical Development
The sponsor’s clinical research spans multiple countries and collaborating sites, supporting studies in both rare disease and specialty therapeutic settings.
- International trial sites
- Rare disease research
- Specialty medicine
- Cross-border enrollment
This footprint is aligned with therapeutic development in diseases requiring specialized clinical expertise and coordinated patient access.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Usnoflast in Adults with Amyotrophic Lateral Sclerosis |  Belgium France Germany Ireland Italy Poland Spain Sweden The Netherlands | Recruiting |
| Efficacy and Safety Evaluation of Saroglitazar Magnesium in Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2b/3 Trial |  Iceland | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 27 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
- 2.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
27 centres- Address
- Via Sergio Pansini 5, 80131 Naples
- Address
- Largo Del Pozzo 71, 41124 Modena
- Address
- Beaumont Road, Beaumont, D09 V2N0 Dublin
- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- 2 Avenue Martin Luther King, 87000 Limoges
- Address
- 2 Boulevard Tonnelle, 37044 Tours
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Zydus Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.